Vanguard Group’s Vaxcyte PCVX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $390M | Sell |
11,997,085
-46,720
| -0.4% | -$1.52M | 0.01% | 1166 |
|
|
2025
Q1 | $455M | Buy |
12,043,805
+82,118
| +0.7% | +$3.1M | 0.01% | 1044 |
|
|
2024
Q4 | $979M | Buy |
11,961,687
+521,204
| +5% | +$42.7M | 0.02% | 667 |
|
|
2024
Q3 | $1.31B | Buy |
11,440,483
+1,643,488
| +17% | +$188M | 0.02% | 583 |
|
|
2024
Q2 | $740M | Buy |
9,796,995
+59,741
| +0.6% | +$4.51M | 0.01% | 772 |
|
|
2024
Q1 | $665M | Buy |
9,737,254
+1,284,883
| +15% | +$87.8M | 0.01% | 852 |
|
|
2023
Q4 | $531M | Buy |
8,452,371
+168,125
| +2% | +$10.6M | 0.01% | 934 |
|
|
2023
Q3 | $422M | Buy |
8,284,246
+47,872
| +0.6% | +$2.44M | 0.01% | 987 |
|
|
2023
Q2 | $411M | Buy |
8,236,374
+1,704,058
| +26% | +$85.1M | 0.01% | 1041 |
|
|
2023
Q1 | $245M | Sell |
6,532,316
-81,350
| -1% | -$3.05M | 0.01% | 1346 |
|
|
2022
Q4 | $317M | Buy |
6,613,666
+2,161,521
| +49% | +$104M | 0.01% | 1137 |
|
|
2022
Q3 | $107M | Buy |
4,452,145
+496,227
| +13% | +$11.9M | ﹤0.01% | 1747 |
|
|
2022
Q2 | $86.1M | Buy |
3,955,918
+326,554
| +9% | +$7.11M | ﹤0.01% | 1912 |
|
|
2022
Q1 | $87.6M | Buy |
3,629,364
+495,078
| +16% | +$12M | ﹤0.01% | 2016 |
|
|
2021
Q4 | $74.6M | Buy |
3,134,286
+90,404
| +3% | +$2.15M | ﹤0.01% | 2131 |
|
|
2021
Q3 | $77.2M | Buy |
3,043,882
+195,238
| +7% | +$4.95M | ﹤0.01% | 2130 |
|
|
2021
Q2 | $64.1M | Buy |
2,848,644
+77,330
| +3% | +$1.74M | ﹤0.01% | 2238 |
|
|
2021
Q1 | $54.7M | Buy |
2,771,314
+1,321,937
| +91% | +$26.1M | ﹤0.01% | 2264 |
|
|
2020
Q4 | $38.5M | Buy |
1,449,377
+96,557
| +7% | +$2.57M | ﹤0.01% | 2334 |
|
|
2020
Q3 | $66.8M | Buy |
1,352,820
+1,322,820
| +4,409% | +$65.3M | ﹤0.01% | 1871 |
|
|
2020
Q2 | $948K | Buy |
+30,000
| New | +$948K | ﹤0.01% | 3626 |
|